RAD-140: research, sporting claims and risks

What RAD-140 is

RAD-140, also called testolone, is an investigational nonsteroidal androgen receptor modulator. Receptor activity is the reason it appears in both laboratory research and performance-oriented marketing. The existence of a clinical development programme does not make a catalogue item an approved treatment, nor does it show that results in one disease setting apply to healthy users.

What the named research shows

LoRusso and colleagues, Clinical Breast Cancer (2022; DOI 10.1016/j.clbc.2021.08.003), reported a phase I study in 22 women with metastatic breast cancer. Liver-test abnormalities were among the reported adverse events. The registered programme is NCT03088527.

Oncology safety research is not a trial of bodybuilding benefits.

Why it is discussed in sport

Strength and muscle-gain claims are commonly attached to RAD-140 in sport discussions. An oncology phase I study asks about tolerability, pharmacokinetics and early disease-related signals in a particular patient population. It does not answer whether healthy lifters become stronger or whether any change is sustainable. Calling it human research without naming the population removes the context needed to understand the evidence.

Risks and unresolved questions

The oncology population makes a direct estimate of harm in healthy athletes inappropriate, but it does not justify dismissing the liver findings. Early studies are not large enough to establish uncommon or long-term harms. FDA class warnings also include liver injury. Product substitution, combinations and uncertain identity create questions that the clinical paper did not test.

Reading product claims alongside evidence

A research publication and a retail product answer different questions. The image shows the actual source packaging for recognition. It does not confirm contents, purity, sterility or suitability. A particular batch would require traceable sampling, identity testing and appropriate analytical documentation. A percentage printed on a label alone does not replace that documentation.

This overview separates observed results from extrapolation to athletes. It provides no use protocol. Potential benefits are described as studied signals or as claims in sporting discussions; missing long-term data are not treated as reassurance. New publications can change the assessment. The draft still requires editorial review before publication.